Clinical trial
Ertugliflozin: Cardioprotective Effects on Epicardial Fat
NCT04167761 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Ertugliflozin: Cardioprotective Effects on Epicardial Fat
- Lead sponsor
- Stanford University
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- July 1, 2020
- Completion date
- December 31, 2023
- Enrollment
- 61 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
atherosclerosis, cardiovascular diseases, insulin resistance, type 2 diabetes